【Happy News】Yonghe Sunshine tumor marker series is approved for marketing!

CEA Carcinoembryonic Antigen

CEA is a complex structured acidic glycoprotein, which is mainly found in adult cancer tissues as well as fetal gastrointestinal tube tissues, and is a broader spectrum tumor marker. It is a broad-spectrum tumor marker. It can be used clinically as an aid in the diagnosis of colon cancer, rectal cancer, lung cancer, breast cancer, esophageal cancer, pancreatic cancer, gastric cancer, metastatic liver cancer and other common tumors.

NSE Neuron-specific enolase

NSE is an enzyme specific to neurons and neuroendocrine cells. As a sensitive indicator to evaluate the severity of neuronal cell injury and judge the prognosis, NSE is widely used in various neurological injuries, such as cerebral hemorrhage, ischemia, hypoxia, infection, poisoning, and malnutrition. At the same time, the content of NSE is high in neuroendocrine cells, so it is also often used in the diagnosis and prognosis evaluation of small cell lung cancer.

CA19-9 Glycoantigen 19-9

CA19-9 is a glycolipid on the cell membrane and exists in serum as salivary mucin. Its serum concentration is significantly increased in patients with GI tumors. When suffering from pancreatic cancer, colorectal cancer, gastric cancer and liver cancer, the level of CA19-9 in blood can be significantly increased, which is a good indicator for the detection of GI malignancies.

CA50 Glycoantigen 50

CA50 is a blood type antigen tumor marker, a derivative of sialic acid fucose. CA50 is a macromolecular glycoprotein, which is widely found in epithelial tumors, and is a non-specific broad-spectrum tumor marker with some cross-antigenic properties with CA19-9.

CA242 Glycoantigen 242

CA242 is a salivary acidified mucin-type glycoprotein. It is a novel tumor marker that has a relatively good prognostic effect on GI tract tumors. In the diagnosis of pancreatic cancer it has a higher sensitivity than glycoantigen 19-9 (CA19-9), which can reach 66%-100%. It also has a high sensitivity and better accuracy in colorectal cancer, and it has some auxiliary diagnostic effect on malignant tumors such as gallbladder cancer, lung cancer, esophageal cancer and breast cancer.

ProGRP Gastrin-releasing peptide precursor

ProGRP can be secreted by small cell lung cancer (SCLS) tumor cells and is an important serum diagnostic marker for SCLS. Its specificity and sensitivity are higher than other lung cancer-related indicators such as NSE and CYFRA21-1, and it has important guiding values in the diagnosis, recurrence and metastasis determination, efficacy monitoring and prognosis evaluation of SCLS.

CYFRA21-1 cytokeratin 19 fragment

CYFRA21-1 is the smallest member of the keratin family. CYFRA21-1 is widely distributed in normal tissue surfaces, such as lamellar or squamous epithelium. It is the first tumor marker of choice for detection of non-small cell lung cancer.

The tumor marker series certified this time marks the further enrichment of YSP's magnetic particle chemiluminescence product line, and is also an important step for YSP to move to a higher starting point! In the future, Yonghe Sunshine will also uphold the tenet of innovative technology and leading health, increase investment in R&D, adhere to continuous innovation, recruit and retain talents in multiple forms, further enhance the comprehensive R&D capability of the enterprise technology center, and provide comprehensive competitiveness of the company. Yonghe Sunshine will actively respond to the national call and make more efforts to reach the visionary goal of "Healthy China" in 2035!